Mati Fridkin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10623343/publications.pdf

Version: 2024-02-01

224 papers	8,980 citations	34016 52 h-index	54797 84 g-index
226 all docs	226 docs citations	226 times ranked	6956 citing authors

#	Article	IF	Citations
1	Albuminâ€“Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells. Pharmaceutics, 2022, 14, 71.	2.0	2
2	Therapeutic Potential of Vasoactive Intestinal Peptide and its Derivative Stearyl-Norleucine-VIP in Inflammation-Induced Osteolysis. Frontiers in Pharmacology, 2021, 12, 638128.	1.6	7
3	Albumin-EDTA-Vanadium Is a Powerful Anti-Proliferative Agent, Following Entrance into Glioma Cells via Caveolae-Mediated Endocytosis. Pharmaceutics, 2021, 13, 1557.	2.0	3
4	From Anti-Parkinsonâ€™s Drug Rasagiline to Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimerâ€™s Disease. , 2020, , 1-26.		1
5	Converting bleomycin into a prodrug that undergoes spontaneous reactivation under physiological conditions. Toxicology and Applied Pharmacology, 2019, 384, 114782.	1.3	4
6	Helminth-Based Product and the Microbiome of Mice with Lupus. MSystems, 2019, 4, .	1.7	22
7	The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. Journal of Autoimmunity, 2019, 98, 113-121.	3.0	7
8	Helminths-based bi-functional molecule, tuftsin-phosphorylcholine (TPC), ameliorates an established murine arthritis. PLoS ONE, 2018, 13, e0200615.	1.1	17
9	Tuftsin-Phosphorylcholine Maintains Normal Gut Microbiota in Collagen Induced Arthritic Mice. Frontiers in Microbiology, 2017, 8, 1222.	1.5	25
10	Conjugation of Methotrexate-Amino Derivatives to Macromolecules through Carboxylate Moieties Is Superior Over Conventional Linkage to Amino Residues: Chemical, Cell-Free and In Vitro Characterizations. PLoS ONE, 2016, 11, e0158352.	1.1	2
11	Combined Local Bloodâ€“Brain Barrier Opening and Systemic Methotrexate for the Treatment of Brain Tumors. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 967-976.	2.4	22
12	New Approaches to Treating Alzheimer's Disease. Perspectives in Medicinal Chemistry, 2015, 7, PMC.S13210.	4.6	32
13	Successful modulation of murine lupus nephritis with tuftsin-phosphorylcholine. Journal of Autoimmunity, 2015, 59, 1-7.	3.0	36
14	Phosphorylcholine-tuftsin compound prevents development of dextransulfate-sodium-salt induced murine colitis: Implications for the treatment of human inflammatory bowel disease. Journal of Autoimmunity, 2015, 56, 111-117.	3.0	32
15	From Single Target to Multitarget/Network Therapeutics in Alzheimerâ€™s Therapy. Pharmaceuticals, 2014, 7, 113-135.	1.7	94
16	Research Spotlight: Establishing the principle of reversibility in peptide/protein and small-molecule therapy. Therapeutic Delivery, 2012, 3, 17-23.	1.2	1
17	Peptide Derived from HIV-1 TAT Protein Destabilizes a Monolayer of Endothelial Cells in an in Vitro Model of the Blood-Brain Barrier and Allows Permeation of High Molecular Weight Proteins. Journal of Biological Chemistry, 2012, 287, 44676-44683.	1.6	20
18	Newly Designed Modifier Prolongs the Action of Short-Lived Peptides and Proteins by Allowing Their Binding to Serum Albumin. Bioconjugate Chemistry, 2012, 23, 1577-1586.	1.8	10

#	Article	IF	Citations
19	From Anti-Parkinson's Drug Rasagiline to Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 30, 1-16.	1.2	68
20	Novel Chelators Targeting Cell Cycle Arrest, Acetylcholinesterase, and Monoamine Oxidase for Alzheimer's Therapy. Current Drug Targets, 2012, 13, 1096-1113.	1.0	12
21	Î²2-Glycoprotein-I based peptide regulate endothelial-cells tissue-factor expression via negative regulation of pGSK3Î² expression and reduces experimental-antiphospholipid-syndrome. Journal of Autoimmunity, 2011, 37, 8-17.	3.0	23
22	Selective Acetylcholinesterase Inhibitor Activated by Acetylcholinesterase Releases an Active Chelator with Neurorescuing and Anti-Amyloid Activities. ACS Chemical Neuroscience, 2010, 1, 737-746.	1.7	45
23	Towards the Efficiency of Pharmacologically Active Quinoid Compounds: Electron Transfer and Formation of Reactive Oxygen Species. Applied Magnetic Resonance, 2010, 37, 629-648.	0.6	21
24	Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP Treatment by the Novel Multifunctional Brain-Permeable Iron Chelator-Monoamine Oxidase Inhibitor Drug, M30. Neurotoxicity Research, 2010, 17, 15-27.	1.3	68
25	Site-Activated Chelators Derived from Anti-Parkinson Drug Rasagiline as a Potential Safer and More Effective Approach to the Treatment of Alzheimerâ€™s Disease. Neurochemical Research, 2010, 35, 2117-2123.	1.6	30
26	Site-Activated Chelators Targeting Acetylcholinesterase and Monoamine Oxidase for Alzheimerâ€™s Therapy. ACS Chemical Biology, 2010, 5, 603-610.	1.6	94
27	Relation between Serum Amyloid A Truncated Peptides and Their Suprastructure Chirality. Journal of the American Chemical Society, 2010, 132, 4242-4248.	6.6	45
28	Restrain of bone growth by Estrogen-Mimetic Peptide-1 (EMP-1): A micro-computed tomographic study. Peptides, 2009, 30, 1181-1186.	1.2	4
29	Site-Activated Multifunctional Chelator with Acetylcholinesterase and Neuroprotectiveâ^'Neurorestorative Moieties for Alzheimerâ€™s Therapy. Journal of Medicinal Chemistry, 2009, 52, 4095-4098.	2.9	129
30	Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability. Journal of Peptide Science, 2008, 14, 321-328.	0.8	20
31	Conjugates of gonadotropin releasing hormone (GnRH) with carminic acid: Synthesis, generation of reactive oxygen species (ROS) and biological evaluation. Bioorganic and Medicinal Chemistry, 2008, 16, 6789-6798.	1.4	15
32	Turning Low-Molecular-Weight Drugs into Prolonged Acting Prodrugs by Reversible Pegylation: A Study with Gentamicin. Journal of Medicinal Chemistry, 2008, 51, 4300-4305.	2.9	27
33	Reversible Pegylation Prolongs the Hypotensive Effect of Atrial Natriuretic Peptide. Bioconjugate Chemistry, 2008, 19, 342-348.	1.8	17
34	Chirality of Amyloid Suprastructures. Journal of the American Chemical Society, 2008, 130, 4602-4603.	6.6	130
35	A Novel Iron-Chelating Derivative of the Neuroprotective Peptide NAPVSIPQ Shows Superior Antioxidant and Antineurodegenerative Capabilities. Journal of Medicinal Chemistry, 2008, 51, 126-134.	2.9	42
36	Pneumococcal Capsular Polysaccharide Is Immunogenic When Present on the Surface of Macrophages and Dendritic Cells: TLR4 Signaling Induced by a Conjugate Vaccine or by Lipopolysaccharide Is Conducive. Journal of Immunology, 2008, 180, 2409-2418.	0.4	25

#	Article	IF	Citations
37	The Design, Synthesis, and Biological Evaluation of VIP and VIP Analogs. Neuromethods, 2008, , 1-9.	0.2	0
38	Prevention and restoration of lactacystinâ€induced nigrostriatal dopamine neuron degeneration by novel brainâ€permeable iron chelators. FASEB Journal, 2007, 21, 3835-3844.	0.2	131
39	Novel Multifunctional Anti-Alzheimer Drugs with Various CNS Neurotransmitter Targets and Neuroprotective Moieties. Current Alzheimer Research, 2007, 4, 522-536.	0.7	28
40	Neurorescue Activity, APP Regulation and Amyloid-β Peptide Reduction by Novel Multi-Functional Brain Permeable Iron- Chelating- Antioxidants,M-30 and Green Tea Polyphenol, EGCG. Current Alzheimer Research, 2007, 4, 403-411.	0.7	106
41	Novel analogs of VIP with multiple C-terminal domains. Peptides, 2007, 28, 1622-1630.	1.2	5
42	Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator?monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. Journal of Neurochemistry, 2007, 100, 490-502.	2.1	128
43	Hypericin Derivatives: Substituent Effects on Radical-anion Formation. Photochemistry and Photobiology, 2007, 74, 149-156.	1.3	0
44	Generation of Free Radicals by Emodic Acid and its [d-Lys6]GnRH-conjugateÂ¶. Photochemistry and Photobiology, 2007, 74, 226-236.	1.3	1
45	Novel extended and branched N-terminal analogs of VIP. Regulatory Peptides, 2006, 137, 42-49.	1.9	8
46	Novel cyclic azo-bridged analogs of gonadotropin-releasing hormone. Journal of Peptide Science, 2006, 12, 106-115.	0.8	6
47	Synthesis and Active Oxygen Generation by New Emodin Derivatives and Their Gonadotropin-Releasing Hormone Conjugates. Bioconjugate Chemistry, 2006, 17, 1008-1016.	1.8	15
48	Polymyxin B and Related Cyclic Peptides Facilitate Leanness and Reduce Fat Mass and Triglyceride Content in Ageing Rats: Potential Prototype Drugs Against Obesity. International Journal of Peptide Research and Therapeutics, 2006, 12, 121-129.	0.9	3
49	Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimerâ€™s, Parkinsonâ€™s, and other neurodegenerative diseases. Bioorganic and Medicinal Chemistry, 2005, 13, 773-783.	1.4	263
50	Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. Journal of Neurochemistry, 2005, 95, 68-78.	2.1	194
51	Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. Inâ€ƒvivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. Journal of Neurochemistry, 2005, 95, 79-88.	2.1	175
52	Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. Biochemical Pharmacology, 2005, 70, 1642-1652.	2.0	52
53	Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mechanisms of Ageing and Development, 2005, 126, 317-326.	2.2	123
54	Tuftsin-AZT conjugate: potential macrophage targeting for AIDS therapy. Journal of Peptide Science, 2005, 11, 37-44.	0.8	26

#	Article	IF	Citations
55	Novel Methyl Helianthrones as Photosensitizers: Synthesis and Biological EvaluationÂ¶. Photochemistry and Photobiology, 2005, 81, 250.	1.3	4
56	Neopeptide Antibiotics That Function as Opsonins and Membrane-Permeabilizing Agents for Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2005, 49, 3122-3128.	1.4	28
57	Albuminâ^'Insulin Conjugate Releasing Insulin Slowly under Physiological Conditions:â€‰ A New Concept for Long-Acting Insulin. Bioconjugate Chemistry, 2005, 16, 913-920.	1.8	30
58	Reversible PEGylation of peptide YY3-36prolongs its inhibition of food intake in mice. FEBS Letters, 2005, 579, 2439-2444.	1.3	40
59	Novel Methyl Helianthrones as Photosensitizers: Synthesis and Biological Evaluation^{Â¶}. Photochemistry and Photobiology, 2005, 81, 250-258.	1.3	0
60	Design, synthesis, and evaluation of peptides with estrogen-like activity. Biopolymers, 2004, 76, 404-420.	1.2	6
61	Prolonging the Action of Protein and Peptide Drugs by a Novel Approach of Reversible Polyethylene Glycol Modification. Journal of Biological Chemistry, 2004, 279, 38118-38124.	1.6	67
62	Reversible PEGylation:Â A Novel Technology To Release Native Interferon Î±2 over a Prolonged Time Period. Journal of Medicinal Chemistry, 2004, 47, 4897-4904.	2.9	63
63	Backbone metal cyclization: Novel 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer. Nuclear Medicine and Biology, 2004, 31, 921-933.	0.3	48
64	A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo. Journal of Autoimmunity, 2004, 22, 217-225.	3.0	51
65	The binding site for _-bungarotoxin in the acetylcholine receptor. , 2004, , 19-25.		0
66	From Vasoactive Intestinal Peptide (VIP) Through Activity-Dependent Neuroprotective Protein (ADNP) to NAP: A View of Neuroprotection and Cell Division. Journal of Molecular Neuroscience, 2003, 20, 315-322.	1.1	91
67	The Binding Site of Acetylcholine Receptor. Annals of the New York Academy of Sciences, 2003, 998, 93-100.	1.8	20
68	Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium-based drugs for diabetes. Coordination Chemistry Reviews, 2003, 237, 3-11.	9.5	214
69	Receptor-Mediated Targeting of a Photosensitizer by Its Conjugation to Gonadotropin-Releasing Hormone Analogues. Journal of Medicinal Chemistry, 2003, 46, 3965-3974.	2.9	55
70	Chemical and Photochemical Electron Transfer of New Helianthrone Derivatives:Â Aspects of Their Photodynamic Activity. Journal of the American Chemical Society, 2003, 125, 1376-1384.	6.6	38
71	[2-Sulfo-9-fluorenylmethoxycarbonyl]3â€“exendin-4â€”a long-acting glucose-lowering prodrug. Biochemical and Biophysical Research Communications, 2003, 305, 386-391.	1.0	13
72	Lipid binding and membrane penetration of polymyxin B derivatives studied in a biomimetic vesicle system. Biochemical Journal, 2003, 375, 405-413.	1.7	53

#	Article	IF	Citations
73	Modulation of the Hydrophobic Domain of Polymyxin B Nonapeptide: Effect on Outer-Membrane Permeabilization and Lipopolysaccharide Neutralization. Molecular Pharmacology, 2002, 62, 1036-1042.	1.0	62
74	NAP, a Femtomolar-Acting Peptide, Protects the Brain Against Ischemic Injury by Reducing Apoptotic Death. Stroke, 2002, 33, 1085-1092.	1.0	120
75	Adhesion of human platelets to serum amyloid A. Blood, 2002, 99, 1224-1229.	0.6	87
76	N-[(2-Sulfo)-9-fluorenylmethoxycarbonyl]3-gentamicin C1Is a Long-Acting Prodrug Derivative. Journal of Medicinal Chemistry, 2002, 45, 4264-4270.	2.9	15
77	A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes. Life Sciences, 2002, 71, 2543-2552.	2.0	11
78	The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase. Regulatory Peptides, 2002, 108, 175-177.	1.9	8
79	In vitro and in vivo treatment of colon cancer by VIP antagonists. Regulatory Peptides, 2002, 109, 127-133.	1.9	23
80	Potentiating vanadium-evoked glucose metabolism by novel hydroxamate derivatives. International Journal of Peptide Research and Therapeutics, 2002, 9, 235-254.	0.1	0
81	Design and synthesis of peptides that bind Î±-bungarotoxin with high affinity and mimic the three-dimensional structure of the binding-site of acetylcholine receptor. Biophysical Chemistry, 2002, 100, 293-305.	1.5	25
82	Potentiating vanadium-evoked glucose metabolism by novel hydroxamate derivatives. International Journal of Peptide Research and Therapeutics, 2002, 9, 235-254.	0.1	1
83	(N-stearyl, Norleucine¹⁷)VIPhybrid is a Broad Spectrum Vasoactive Intestinal Peptide Receptor Antagonist. Journal of Molecular Neuroscience, 2002, 18, 29-36.	1.1	23
84	Bacterial induction of autoantibodies to Î²2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. Journal of Clinical Investigation, 2002, 109, 797-804.	3.9	238
85	Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures. Neuroscience Letters, 2001, 307, 167-170.	1.0	36
86	The Binding Site of Acetylcholine Receptor as Visualized in the X-Ray Structure of a Complex between Î±-Bungarotoxin and a Mimotope Peptide. Neuron, 2001, 32, 265-275.	3.8	125
87	Design, Synthesis, and Evaluation of a Long-Acting, Potent Analogue of Gonadotropin-Releasing Hormone. Journal of Medicinal Chemistry, 2001, 44, 3645-3652.	2.9	14
88	Hypericin Derivatives: Substituent Effects on Radical-anion Formation. Photochemistry and Photobiology, 2001, 74, 149.	1.3	10
89	A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines. Cancer, 2001, 92, 2172-2180.	2.0	33
90	VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Research and Treatment, 2001, 68, 55-64.	1.1	47

#	Article	IF	Citations
91	VIP and Peptides Related to Activity-Dependent Neurotrophic Factor Protect PC12 Cells Against Oxidative Stress. Journal of Molecular Neuroscience, 2001, 15, 137-146.	1.1	69
92	VIP-Related Protection Against Iodoacetate Toxicity in Pheochromocytoma (PC12) Cells: A Model for Ischemic/Hypoxic Injury. Journal of Molecular Neuroscience, 2001, 15, 147-154.	1.1	53
93	A Vasoactive Intestinal Peptide Antagonist Inhibits the Growth of Glioblastoma Cells. Journal of Molecular Neuroscience, 2001, 17, 331-340.	1.1	26
94	Design and synthesis of peptides that bind Î±-bungarotoxin with high affinity. Chemistry and Biology, 2001, 8, 147-155.	6.2	46
95	SH2 Domain-Containing Inositol Polyphosphate 5â€²-Phosphatase Is the Main Mediator of the Inhibitory Action of the Mast Cell Function-Associated Antigen. Journal of Immunology, 2001, 167, 6394-6402.	0.4	54
96	Generation of Free Radicals by Emodic Acid and its [d-Lys6]GnRH-conjugateÂ¶. Photochemistry and Photobiology, 2001, 74, 226.	1.3	24
97	Intranasal Delivery of Bioactive Peptides or Peptide Analogues Enhances Spatial Memory and Protects Against Cholinergic Deficits. , 2001, , 363-370.		1
98	Organic Vanadium Chelators Potentiate Vanadium-Evoked Glucose Metabolism In Vitro and In Vivo: Establishing Criteria for Optimal Chelators. Molecular Pharmacology, 2000, 58, 738-746.	1.0	37
99	Novel breast-tumor-associated MUC1-derived peptides: Characterization in Dbâ^'/â^' Ã— Î²2 microglobulin (Î²2m) null mice transgenic for a chimeric HLA-A2.1/Db-Î²2 microglobulin single chain. International Journal of Cancer, 2000, 85, 391-397.	2.3	40
100	An immunoreceptor tyrosine-based inhibitory motif, with serine at site Y-2, binds SH2-domain-containing phosphatases. FEBS Journal, 2000, 267, 703-711.	0.2	17
101	Insulin-like effects of vanadium: basic and clinical implications. Journal of Inorganic Biochemistry, 2000, 80, 21-25.	1.5	142
102	Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease1This manuscript is based on a poster presented at the Brain Research Interactive Symposium on â€œNeuropeptides at the Millenniumâ€, Miami, October 1999.1. Brain Research, 2000, 854, 257-262.	1.1	147
103	Immune response of SLE patients to peptides based on the complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Journal of Clinical Immunology, 2000, 20, 187-194.	2.0	26
104	A Peptide Based on the Sequence of the CDR3 of a Murine Anti-DNA mAb Is a Better Modulator of Experimental SLE Than Its Single Amino Acid-Substituted Analogs. Cellular Immunology, 2000, 205, 52-61.	1.4	5
105	Vanadate restores glucose 6-phosphate in diabetic rats: a mechanism to enhance glucose metabolism. American Journal of Physiology - Endocrinology and Metabolism, 2000, 279, E403-E410.	1.8	17
106	A Peptide Based on the CDR1 of a Pathogenic anti-DNA Antibody is more Efficient than its Analogs in Inhibiting Autoreactive T Cells. Immunobiology, 2000, 202, 383-393.	0.8	5
107	Serum amyloid A-derived peptides, present in human rheumatic synovial fluids, induce the secretion of interferon-Î³ by human CD4 + T-lymphocytes. FEBS Letters, 2000, 472, 259-262.	1.3	33
108	VIP and the potent analog, stearyl-Nle17 -VIP, induce proliferation of keratinocytes. FEBS Letters, 2000, 475, 78-83.	1.3	39

#	Article	IF	Citations
109	VIP-derived sequences modified by N-terminal stearyl moiety induce cell death: the human keratinocyte as a model. FEBS Letters, 2000, 475, 71-77.	1.3	17
110	A Novel Approach for a Water-Soluble Long-Acting Insulin Prodrug:Â Design, Preparation, and Analysis of [(2-Sulfo)-9-fluorenylmethoxycarbonyl]3-insulin. Journal of Medicinal Chemistry, 2000, 43, 2530-2537.	2.9	33
111	The Functional Association of Polymyxin B with Bacterial Lipopolysaccharide Is Stereospecific:Â Studies on Polymyxin B Nonapeptideâ€. Biochemistry, 2000, 39, 11837-11844.	1.2	75
112	Design and Synthesis of Potent Hexapeptide and Heptapeptide Gonadotropin-Releasing Hormone Antagonists by Truncation of a Decapeptide Analogue Sequence. Journal of Medicinal Chemistry, 2000, 43, 2831-2836.	2.9	10
113	Structureâ^'Activity Studies of Reduced-Size Gonadotropin-Releasing Hormone Agonists Derived from the Sequence of an Endothelin Antagonist. Journal of Medicinal Chemistry, 2000, 43, 2824-2830.	2.9	9
114	Structureâ^'Function Studies of Polymyxin B Nonapeptide:Â Implications to Sensitization of Gram-Negative Bacteria#. Journal of Medicinal Chemistry, 2000, 43, 3085-3092.	2.9	139
115	Self Heatâ€Shock Protein (hsp60) Peptide Serves in a Conjugate Vaccine against a Lethal Pneumococcal Infection. Journal of Infectious Diseases, 1999, 179, 403-413.	1.9	33
116	l-Glutamic Acid Î³-Monohydroxamate. Journal of Biological Chemistry, 1999, 274, 26617-26624.	1.6	37
117	Immunogenicity of H-2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccination. Immunology Letters, 1999, 70, 21-28.	1.1	12
118	Title is missing!. International Journal of Peptide Research and Therapeutics, 1999, 6, 99-108.	0.1	0
119	A study of extracellular matrix-cell adhesion peptidic epitopes related to human serum amyloid A (SAA). International Journal of Peptide Research and Therapeutics, 1999, 6, 99-108.	0.1	0
120	MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. European Journal of Immunology, 1999, 29, 3295-3301.	1.6	79
121	Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms. Regulatory Peptides, 1999, 84, 55-67.	1.9	29
122	SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival. Peptides, 1999, 20, 629-633.	1.2	22
123	Synthesis and bioactivity of fatty acid-conjugated GnRH derivatives. Life Sciences, 1999, 64, 1543-1552.	2.0	11
124	The gonadotropin-releasing hormone family of neuropeptides in the brain of human, bovine and rat: identification of a third isoform. FEBS Letters, 1999, 463, 289-294.	1.3	59
125	MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. , 1999, 29, 3295.		1
126	Cytotoxic Peptides: Naphthoquinonyl Derivatives of Luteinizing Hormone-Releasing Hormone. International Journal of Peptide Research and Therapeutics, 1998, 5, 421-427.	0.1	0

#	Article	IF	Citations
127	Title is missing!. International Journal of Peptide Research and Therapeutics, 1998, 5, 349-355.	0.1	4
128	Tumor-Associated Antigen Peptides as Anti-Metastatic Vaccines. International Journal of Peptide Research and Therapeutics, 1998, 5, 323-328.	0.1	0
129	Protection against developmental deficiencies by a lipophilic VIP analogue. Neurochemical Research, 1998, 23, 689-693.	1.6	12
130	Multiple Actions of a Hybrid PACAP Antagonist: Neuronal Cell Killing and Inhibition of Sperm Motilitya. Annals of the New York Academy of Sciences, 1998, 865, 266-273.	1.8	9
131	Effect of serum amyloid A on selected in vitro functions of isolated human neutrophils. Translational Research, 1998, 132, 414-420.	2.4	44
132	Tumor-associated antigen peptides as anti-metastatic vaccines. International Journal of Peptide Research and Therapeutics, 1998, 5, 323-328.	0.1	0
133	Serum amyloid A complexed with extracellular matrix induces the secretion of tumor necrosis factor-Î± by human T-lymphocytes. International Journal of Peptide Research and Therapeutics, 1998, 5, 349-355.	0.1	6
134	Cytotoxic peptides: Naphthoquinonyl derivatives of luteinizing hormone-releasing hormone. International Journal of Peptide Research and Therapeutics, 1998, 5, 421-427.	0.1	5
135	Single amino acid analogs of a myasthenogenic peptide modulate specific T cell responses and prevent the induction of experimental autoimmune myasthenia gravis. Journal of Neuroimmunology, 1998, 85, 78-86.	1.1	21
136	Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Tumor Necrosis Factor Î± Transcriptional Activation by Regulating Nuclear Factor-kB and cAMP Response Element-binding Protein/c-Jun. Journal of Biological Chemistry, 1998, 273, 31427-31436.	1.6	165
137	Insulin-like Effects of Vanadium; Reviewing In Vivo and In Vitro Studies and Mechanisms of Action. ACS Symposium Series, 1998, , 308-315.	0.5	9
138	Involvement of Pituitary Adenylate Cyclaseâ€Activating Polypeptide II Vasoactive Intestinal Peptide 2 Receptor in Mouse Neocortical Astrocytogenesis. Journal of Neurochemistry, 1998, 70, 2165-2173.	2.1	53
139	Peptides derived from human Câ€reaetive protein inhibit the enzymatic activities of human leukocyte elastase and cathepsin G: use of overlapping peptide sequences to identify a unique inhibitor. Chemical Biology and Drug Design, 1998, 51, 282-289.	1.2	9
140	Preventive Treatment of Alzheimerâ€™s Disease. Advances in Behavioral Biology, 1998, , 635-642.	0.2	0
141	Mast Cell Adhesion to Extracellular Matrix: Local Effects of Acute Phase Reactants. International Archives of Allergy and Immunology, 1997, 113, 295-296.	0.9	6
142	Neurobehavioral Development of Neonatal Mice Following Blockade of VIP During the Early Embryonic Period. Peptides, 1997, 18, 1131-1137.	1.2	49
143	Title is missing!. International Journal of Peptide Research and Therapeutics, 1997, 4, 157.	0.1	0
144	Inhibition of human leukocyte elastase and cathepsin G by extended peptides and subunits derived from human C-reactive protein. International Journal of Peptide Research and Therapeutics, 1997, 4, 157-166.	0.1	0

#	Article	IF	Citations
145	Tuftsinâ€“THF-Î³2 chimeric peptides: potential novel immunomodulators. Immunopharmacology, 1997, 37, 43-52.	2.0	5
146	Characterizing immunodominant and protective influenza hemagglutinin epitopes by functional activity and relative binding to major histocompatibility complex class II sites. European Journal of Immunology, 1997, 27, 3105-3114.	1.6	25
147	Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: Implications for early treatment of Alzheimer's disease. , 1997, 33, 329-342.		59
148	1-Aminocyclobutanecarboxylic Acid Derivatives as Novel Structural Elements in Bioactive Peptides:Â Application to Tuftsin Analogs. Journal of Medicinal Chemistry, 1996, 39, 4833-4843.	2.9	51
149	Novel naphthoquinonyl derivatives: Potential structural components for the synthesis of cytotoxic peptides. International Journal of Peptide Research and Therapeutics, 1996, 3, 263-274.	0.1	18
150	Synthetic peptides derived from the sequence of human Câ€reactive protein inhibit the enzymatic activities of human leukocyte elastase and human leukocyte cathepsin G. International Journal of Peptide and Protein Research, 1996, 48, 465-476.	0.1	6
151	Binding of human serum amyloid A (hSAA) and its highâ€density lipoprotein₃ complex (hSAAâ€HDL₃) to human neutrophils. Possible implication to the function of a protein of an unknown physiological role. International Journal of Peptide and Protein Research, 1996, 48, 503-513.	0.1	12
152	A VIP hybrid antagonist: From developmental neurobiology to clinical applications. Cellular and Molecular Neurobiology, 1995, 15, 675-687.	1.7	21
153	Proteolysis of human C-reactive protein by neutrophil-derived lysosomal enzymes generates peptides which modulate neutrophil function: Implication to the anti-inflammatory mechanism. International Journal of Peptide Research and Therapeutics, 1995, 2, 7-16.	0.1	3
154	Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nature Medicine, 1995, 1, 1179-1183.	15.2	143
155	The 2,4â€dinitrophenyl group for protection of hydroxyl function of tyrosine during solidâ€phase peptide synthesis. International Journal of Peptide and Protein Research, 1995, 45, 116-121.	0.1	13
156	CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature, 1994, 369, 67-71.	13.7	254
157	Inhibition of cell adhesion to glycoproteins of the extracellular matrix by peptides corresponding to serum amyloid A. Toward understanding the physiological role of an enigmatic protein. FEBS Journal, 1994, 223, 35-42.	0.2	59
158	Binding of human serum amyloid P component (hSAP) to human neutrophils. FEBS Journal, 1994, 223, 805-811.	0.2	24
159	Blockade of VIP during Neonatal Development Induces Neuronal Damage and Increases VIP and VIP Receptors in Brain. Annals of the New York Academy of Sciences, 1994, 739, 211-225.	1.8	30
160	PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP)/VASOACTIVE INTESTINAL PEPTIDE (VIP) RECEPTOR SUBTYPES IN RAT TISSUES: INVESTIGATION OF RECEPTOR BINDING, A NOVEL VIP RECEPTOR ANTAGONIST AND CHEMICAL CROSS-LINKING . Biomedical Research, 1994, 15, 145-153.	0.3	3
161	Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature, 1993, 362, 155-158.	13.7	268
162	Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin. FEBS Letters, 1993, 315, 293-297.	1.3	39

#	Article	IF	Citations
163	Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Research, 1992, 570, 49-53.	1.1	144
164	A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes. Brain Research, 1991, 540, 319-321.	1.1	59
165	Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides, 1991, 12, 187-192.	1.2	76
166	[5] Generation and use of antibodies to phosphothreonine. Methods in Enzymology, 1991, 201, 44-53.	0.4	14
167	Degradation of C-reactive protein (CRP) by neutrophil lysosomal enzymes generates peptidic neutrophil modulators. , 1991, , 898-900.		1
168	Polytuftsin: A potential precursor for slow release of the phagocytosis stimulating peptide tuftsin. International Journal of Biochemistry & Cell Biology, 1990, 22, 193-195.	0.8	6
169	Thiolysis of the 3â€nitroâ€2â€pyridinesulfenyl (Npys) protecting group An approach towards a general deprotection scheme in peptide synthesis. International Journal of Peptide and Protein Research, 1990, 35, 545-549.	0.1	15
170	Vasoactive Intestinal Peptide Potentiates Sexual Behavior: Inhibition by Novel Antagonist*. Endocrinology, 1989, 125, 2945-2949.	1.4	100
171	Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus. Journal of Molecular Neuroscience, 1989, 1, 55-61.	1.1	22
172	Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus. Journal of Molecular Neuroscience, 1989, 1, 55-61.	1.1	32
173	Antibodies directed against phosphothreonine residues as potent tools for studying protein phosphorylation. FEBS Journal, 1989, 182, 343-348.	0.2	21
174	Tuftsin: Its Chemistry, Biology, and Clinical Potentia. Critical Reviews in Biochemistry and Molecular Biology, 1989, 24, 1-40.	2.3	110
175	C-reactive protein decreases protein phosphorylation in stimulated human neutrophils. FEBS Letters, 1988, 237, 173-177.	1.3	13
176	Synthetic Peptides and Their Antibodies in the Analysis of the Acetylcholine Receptor. Annals of the New York Academy of Sciences, 1987, 505, 256-271.	1.8	12
177	Binding of C-reactive protein to human neutrophils. FEBS Letters, 1987, 211, 165-168.	1.3	40
178	Modulation of human neutrophil function by C-reactive protein. FEBS Journal, 1987, 163, 141-146.	0.2	39
179	BINDING OF C-REACTIVE PROTEIN AND RELATED PEPTIDES TO NEUTROPHILS. , 1987, , 239-242.		0
180	Growth hormone releasing factor-like immunoreactivity in human milk. Biochemical and Biophysical Research Communications, 1986, 135, 1084-1089.	1.0	26

#	Article	IF	Citations
181	Tuftsin analogs: synthesis, structure-function relationships, and implications for specificity of tuftsin's bioactivity. Journal of Medicinal Chemistry, 1986, 29, 1961-1968.	2.9	12
182	Synthetic peptides from C-reactive protein containing tuftsin-related sequences. Peptides, 1986, 7, 961-968.	1.2	13
183	The Tuftsin Receptors. , 1986, , 243-280.		6
184	Peptides related to the calcium binding domains II and III of calmodulin. International Journal of Peptide and Protein Research, 1986, 28, 289-297.	0.1	23
185	Cross resistance to esters of methotrexate in a doxorubicin-resistant subline of P388 murine leukemia. Cancer Chemotherapy and Pharmacology, 1985, 15, 31-4.	1.1	4
186	Immunoreactive and biologically active somatostatin in human and sheep milk. FEBS Journal, 1985, 148, 353-357.	0.2	40
187	ANTIBODIES TO SYNTHETIC PEPTIDES AS PROBES FOR THE a-SUBUNIT AND FOR THE CHOLINERGIC BINDING SITE OF THE ACETYLCHOLINE RECEPTOR. , 1985, , 273-282.		1
188	High levels of vasoactive intestinal peptide in human milk. Biochemical and Biophysical Research Communications, 1985, 133, 228-232.	1.0	49
189	Detection of mRNAs containing regulatory peptide coding sequences using synthetic oligodeoxynucleotides. Journal of Cellular Biochemistry, 1984, 26, 147-156.	1.2	24
190	Studies toward the biosynthesis of vasoactive intestinal peptide (VIP). Peptides, 1984, 5, 161-166.	1.2	24
191	Anti-acetylcholine receptor response achieved by immunization with a synthetic peptide from the receptor sequence. Biochemical and Biophysical Research Communications, 1984, 121, 673-679.	1.0	30
192	Receptor-mediated endocytosis of tuftsin by macrophage cells. Biochemical and Biophysical Research Communications, 1984, 119, 203-211.	1.0	18
193	Peptide fragments from the tuftsin containing domain of immunoglobulin G synthesis and biological activity. Biochemical and Biophysical Research Communications, 1983, 115, 193-200.	1.0	9
194	Synthetic Pathways to Tuftsin and Radioimmunoassay. Annals of the New York Academy of Sciences, 1983, 419, 12-22.	1.8	6
195	Tuftsin Receptors. Annals of the New York Academy of Sciences, 1983, 419, 93-106.	1.8	19
196	Tuftsin Binding to Various Macrophage Hybridomas. Annals of the New York Academy of Sciences, 1983, 419, 107-113.	1.8	4
197	Tuftsin Analogs for Probing Its Specific Receptor Site on Phagocytic Cells. FEBS Journal, 1982, 125, 631-638.	0.2	18
198	Functionalization of polystyrene. III. Synthesis of polymeric thiol reagents. Journal of Polymer Science: Polymer Chemistry Edition, 1982, 20, 1469-1487.	0.8	16

#	Article	IF	Citations
199	Luteinizing Hormoneâ€Releasing Hormone and Thyrotropinâ€Releasing Hormone in Human and Bovine Milk. FEBS Journal, 1982, 127, 647-650.	0.2	62
200	Tuftsin, Thr-Lys-Pro-Arg. Molecular and Cellular Biochemistry, 1981, 41, 73-97.	1.4	78
201	Tuftsin, Thr-Lys-Pro-Arg. , 1981, , 73-97.		14
202	POLYMERIC 2â€MERCAPTOPYRIDINE AND 2â€MERCAPTOâ€NITROBENZENE DERIVATIVES: New Reagents for Peptide Synthesis. International Journal of Peptide and Protein Research, 1981, 17, 531-538.	0.1	11
203	On the mechanism of action of the phagocytosis-stimulating peptide tuftsin. Molecular and Cellular Biochemistry, 1980, 30, 71-7.	1.4	60
204	The phagocytosis stimulating peptide tuftsin: Further look into structure-function relationships. Molecular and Cellular Biochemistry, 1980, 30, 165-70.	1.4	14
205	Conformational changes of poly(L-histidyl-L-alanyl-?-L-glutamic acid) in solution. Transition pathways and conformational intermediates. Biopolymers, 1979, 18, 981-993.	1.2	4
206	Tuftsin-macrophage interaction: Specific binding and augmentation of phagocytosis. Journal of Cellular Physiology, 1979, 100, 55-62.	2.0	72
207	FACILE THIOLYTIC REMOVAL OF THE oâ€NITROPHENYLSULPHENYL AMINOâ€PROTECTING GROUP. International Journal of Peptide and Protein Research, 1979, 13, 315-319.	0.1	21
208	Poly(L-histidyl-L-alanyl-?-L-glutamic acid). II. Catalysis ofp-nitrophenyl acetate hydrolysis. Biopolymers, 1978, 17, 1679-1692.	1.2	15
209	Specific binding sites for the phagocytosis stimulating peptide tuftsin on human polymorphonuclear leukocytes and monocytes. Biochemical and Biophysical Research Communications, 1978, 83, 599-606.	1.0	59
210	SYNTHESIS AND BIOLOGICAL ACTIVITY OF TUFTSIN AND OF [O=CTHR¹]â€TUFTSIN. International Journal of Peptide and Protein Research, 1978, 12, 130-138.	0.1	32
211	Tuftsin and some analogs. Biochimica Et Biophysica Acta - General Subjects, 1977, 496, 203-211.	1.1	108
212	Thiolysis of O-2,4-dinitrophenyltyrosines. Archives of Biochemistry and Biophysics, 1977, 178, 517-526.	1.4	16
213	On the Role of Tryptophan in Luteinizing-Hormone-Releasing Hormone (Luliberin). FEBS Journal, 1977, 79, 269-273.	0.2	3
214	Poly(L-histidyl-L-alanyl-Î±-L-glutamic acid). I. Synthesis. Biopolymers, 1977, 16, 2265-2279.	1.2	4
215	A PHOTOLABILE PROTECTING GROUP FOR THE PHENOLIC HYDROXYL FUNCTION OF TYROSINE. International Journal of Peptide and Protein Research, 1977, 9, 91-96.	0.1	18
216	Structural features of luliberin (luteinising hormone-releasing factor) inferred from fluorescence measurements. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1976, 434, 137-143.	1.7	35

#	Article	IF	Citations
217	New Useful Reagents for Peptide Synthesis. Insoluble Active Esters of Polystyrene-Bound 1-Hydroxybenzotriazole. FEBS Journal, 1975, 59, 55-61.	0.2	88
218	(4-Hydroxy-3-nitro)benzylated Polystyrene. An Improved Polymeric Nitrophenol Derivative for Peptide Synthesis. FEBS Journal, 1974, 42, 151-156.	0.2	54
219	Peptide synthesis by means of tert-butyloxycarbonylamino acid derivatives of poly(ethylene-co-N-hydroxymaleimide). Biochemistry, 1972, 11, 466-471.	1.2	36
220	A new route to polyamino acids containing histidine. Archives of Biochemistry and Biophysics, 1971, 147, 767-771.	1.4	18
221	Nonaqueous titrimetric determination of active esters of amino acids and peptide derivatives. Analytical Chemistry, 1970, 42, 275-277.	3.2	11
222	Thiolysis of dinitrophenylimidazoles and its use during synthesis of histidine peptides. Biochemistry, 1970, 9, 5122-5127.	1.2	52
223	Use of polymers as chemical reagents. II. Synthesis of bradykinin. Journal of the American Chemical Society, 1968, 90, 2953-2957.	6.6	73
224	Use of Polymers as Chemical Reagents. I. Preparation of Peptides. Journal of the American Chemical Society, 1966, 88, 3164-3165.	6.6	85